Compare RPC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPC | OLMA |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 949.3M |
| IPO Year | 2021 | 2020 |
| Metric | RPC | OLMA |
|---|---|---|
| Price | $7.50 | $8.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $12.75 | ★ $36.50 |
| AVG Volume (30 Days) | 480.4K | ★ 974.3K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 6.25 | ★ 15.00 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $297,346,000.00 | N/A |
| Revenue This Year | $20.02 | N/A |
| Revenue Next Year | $16.79 | N/A |
| P/E Ratio | $52.44 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $6.79 | $6.65 |
| 52 Week High | $9.51 | $36.26 |
| Indicator | RPC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 31.81 |
| Support Level | $7.54 | N/A |
| Resistance Level | $8.02 | $11.27 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 39.47 | 12.94 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.